The Type II Anti‐CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model
Marinov A, Wang H, Bastacky S, van Puijenbroek E, Schindler T, Speziale D, Perro M, Klein C, Nickerson K, Shlomchik M. The Type II Anti‐CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model. Arthritis & Rheumatology 2021, 73: 826-836. PMID: 33277983, PMCID: PMC8084886, DOI: 10.1002/art.41608.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, Monoclonal, HumanizedB-LymphocytesFlow CytometryImmunologic FactorsKidneyLupus Erythematosus, SystemicLymphocyte DepletionMiceMice, Inbred MRL lprRituximabSkinConceptsMRL/lpr miceB-cell depletionSystemic lupus erythematosusDiseased MRL/lpr miceLpr miceB cellsCell depletionEarly diseaseLupus-prone MRL/lpr micePathogenic B cellsAnti-CD20 antibodyClinical end pointsCD20 monoclonal antibodyMurine lupus modelsMultiple clinical end pointsAmelioration of diseaseAdvanced disease modelsAdvanced diseaseAutoantibody titersLupus nephritisLupus modelsLupus erythematosusInflammatory settingsSingle doseCD20 mAbs